Quadrant Health vs Superluminal Medicines

Side-by-side comparison of AI visibility scores, market position, and capabilities

Superluminal Medicines leads in AI visibility (86 vs 23)
Quadrant Health logo

Quadrant Health

EmergingHealthcare

General

Healthcare population analytics platform for health plans and ACOs; risk stratification, HEDIS quality measures, and predictive models for value-based care management.

AI VisibilityBeta
Overall Score
D23
Category Rank
#981 of 1158
AI Consensus
52%
Trend
up
Per Platform
ChatGPT
32
Perplexity
27
Gemini
18

About

Quadrant Health is a healthcare data analytics and decision support platform helping health plans, providers, and healthcare analytics teams manage population health, identify care gaps, and optimize clinical and financial performance. The company provides tools for risk stratification, utilization management, and quality measure tracking that help healthcare organizations identify high-cost patients, predict future utilization, and intervene proactively to improve outcomes and reduce unnecessary spending.

Full profile
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
A86
Category Rank
#85 of 1158
AI Consensus
59%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
80
Gemini
93

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile

AI Visibility Head-to-Head

23
Overall Score
86
#981
Category Rank
#85
52
AI Consensus
59
up
Trend
stable
32
ChatGPT
83
27
Perplexity
80
18
Gemini
93
14
Claude
83
31
Grok
95

Key Details

Category
General
General
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.